Immunomedics Taps Ipsen’s Harout Semerjian as President and CEO

Immunomedics (NASDAQ: [[ticker:IMMU]]) has appointed Harout Semerjian to serve as its president and CEO. Semerjian is joining the Morris Plains, NJ-based cancer drug developer from Ipsen, where he is executive vice president and chief commercial officer. His experience also includes positions at Novartis (NYSE: [[ticker:NVS]]). Semerjian will start at Immunomedics on April 16. An FDA decision on sacituzumab govitecan, an Immunomedics drug developed for triple-negative breast cancer, is expected by June 2.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan